Stryker Corporation SYK
announced today that its Instruments division has received 510(k) clearance
for the Neptune 2 Waste Management System from the U.S. Food and Drug
Administration (FDA). The Neptune 2 Waste Management System minimizes risk to
healthcare workers by eliminating harmful exposure to fluids and smoke in the
operating room. This constantly closed system collects and disposes of
surgical waste without operator assistance to prevent contact with infectious
fluids and surgical plumes.
With the 510(k) clearance of the Neptune 2, Stryker's commitment has never
been stronger to the surgical waste management market, patient and caregiver
safety and supporting hospital goals related to sustainability, efficiency and
cost optimization. Insight from healthcare workers and perspectives from
regulatory agencies helped create the upgraded Neptune 2 surgical waste
management system. The result is added safety features, greater ease of use,
expanded labeling and training modules, all aimed at helping surgical staff
make the OR environment as modern, safe and efficient as possible.
Beyond the Neptune 2 product upgrades, Stryker is also elevating patient and
caregiver safety with our new, multi-module Continuing Education (CE) Surgical
Suction Academy.
Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array
of innovative medical technologies, including reconstructive, medical and
surgical, and neurotechnology and spine products to help people lead more
active and satisfying lives. For more information about Stryker, please visit
www.stryker.com.
Contacts
For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or yin.becker@stryker.com
For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or
katherine.owen@stryker.com
Forward-Looking Statements
This press release contains information that includes or is based on
forward-looking statements within the meaning of the federal securities law
that are subject to various risks and uncertainties that could cause our
actual results to differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: weakening of
economic conditions that could adversely affect the level of demand for our
products; pricing pressures generally, including cost-containment measures
that could adversely affect the price of or demand for our products; changes
in foreign exchange markets; legislative and regulatory actions; unanticipated
issues arising in connection with clinical studies and otherwise that affect
U.S. Food and Drug Administration approval of new products; changes in
reimbursement levels from third-party payors; a significant increase in
product liability claims; the ultimate total cost with respect to the
Rejuvenate and ABG II matter; the impact of investigative and legal
proceedings and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system; changes in
financial markets; changes in the competitive environment; our ability to
integrate acquisitions, including the acquisition of MAKO Surgical Corp.; and
our ability to realize anticipated cost savings as a result of workforce
reductions and other restructuring activities. Additional information
concerning these and other factors are contained in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on Form 10-K
and Quarterly Reports on Form 10-Q.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in